机构：[1]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, No. 17, HouGou Hu Tong, Dong Cheng District, Beijing 100005, People’s Republic of China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China
BackgroundSubcutaneous immunotherapy (SCIT) is a well-validated and effective disease modification treatment for house dust mites (HDM)-induced allergic rhinitis (AR). Long-term post-treatment comparisons in children and adults treated with SCIT have rarely been published. This study aimed to evaluate the long-term efficacy of HDM-SCIT administered under a cluster schedule in children compared to adults.MethodsThis was an open-design, observational, long-term clinical follow-up study on children and adults with perennial AR treated with HDM-SCIT. The follow-up consisted of a three-year treatment duration plus a post-treatment follow-up of over three years.ResultsPatients in the pediatric (n = 58) and adult (n = 103) groups completed a post-SCIT follow-up of over three years. The total nasal symptom score (TNSS), combined symptom medication score (CSMS), and rhinoconjunctivitis quality-of-life questionnaire (RQLQ) score decreased significantly at T1 (three-year SCIT completed) and T2 (follow-up completed) in the pediatric and adult groups. In both groups, the improvement rate of TNSS (T0-T1) was moderately correlated with the baseline TNSS (r = 0.681, p < 0.001 and r = 0.477, p < 0.001 for children and adults, respectively). Only in the pediatric group, TNSS was significantly lower at T2 compared with that right after SCIT cessation (T1) (p = 0.030).ConclusionsChildren and adults with HDM-induced perennial AR could achieve a sustainable post-treatment efficacy for over three years (up to 13 years) following a three-year SCIT. Patients with relatively severe nasal symptoms at baseline may benefit more from SCIT. Children who have completed an adequate course of SCIT may gain further improvement in nasal symptoms after SCIT cessation.
基金：
This study was supported by the Program for the Changjiang Scholars and
Innovative Research Team (Grant Number IRT13082), the CAMS Innovation
Fund for Medical Sciences (Grant Number 2019-I2M-5-022), National Natural
Science Foundation of China (Grant Number 82071022), Beijing Municipal
Science and Technology Project (Grant Number Z181100001618002), and
Beijing Talents Foundation (grant number 2018000021223ZK14).
第一作者机构：[1]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China[2]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China[3]Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, No. 17, HouGou Hu Tong, Dong Cheng District, Beijing 100005, People’s Republic of China[4]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China
推荐引用方式(GB/T 7714)：
Ren Lei,Wang Chengshuo,Xi Lin,et al.Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis[J].ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY.2023,19(1):doi:10.1186/s13223-023-00781-8.
APA：
Ren, Lei,Wang, Chengshuo,Xi, Lin,Gao, Yunbo,Zhang, Yuan&Zhang, Luo.(2023).Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis.ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY,19,(1)
MLA：
Ren, Lei,et al."Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis".ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY 19..1(2023)
